NATALYA ZAIDAN MALUF
Índice h a partir de 2011
2
Projetos de Pesquisa
Unidades Organizacionais
Instituto de Ortopedia e Traumatologia, Hospital das Clínicas, Faculdade de Medicina
8 resultados
Resultados de Busca
Agora exibindo 1 - 8 de 8
bookPart Imunologia(2016) MALUF, Natalya Zaidan- Cytomegalovirus infection in transplant recipients(2015) AZEVEDO, Luiz Sergio; PIERROTTI, Ligia Camera; ABDALA, Edson; COSTA, Silvia Figueiredo; STRABELLI, Tania Mara Varejao; CAMPOS, Silvia Vidal; RAMOS, Jessica Fernandes; LATIF, Acram Zahredine Abdul; LITVINOV, Nadia; MALUF, Natalya Zaidan; CAIAFFA FILHO, Helio Hehl; PANNUTI, Claudio Sergio; LOPES, Marta Heloisa; SANTOS, Vera Aparecida dos; LINARDI, Camila da Cruz Gouveia; YASUDA, Maria Aparecida Shikanai; MARQUES, Heloisa Helena de SousaCytomegalovirus infection is a frequent complication after transplantation. This infection occurs due to transmission from the transplanted organ, due to reactivation of latent infection, or after a primary infection in seronegative patients and can be defined as follows: latent infection, active infection, viral syndrome or invasive disease. This condition occurs mainly between 30 and 90 days after transplantation. In hematopoietic stem cell transplantation in particular, infection usually occurs within the first 30 days after transplantation and in the presence of graft-versus-host disease. The major risk factors are when the recipient is cytomegalovirus seronegative and the donor is seropositive as well as when lymphocyte-depleting antibodies are used. There are two methods for the diagnosis of cytomegalovirus infection: the pp65 antigenemia assay and polymerase chain reaction. Serology has no value for the diagnosis of active disease, whereas histology of the affected tissue and bronchoalveolar lavage analysis are useful in the diagnosis of invasive disease. Cytomegalovirus disease can be prevented by prophylaxis (the administration of antiviral drugs to all or to a subgroup of patients who are at higher risk of viral replication) or by preemptive therapy (the early diagnosis of viral replication before development of the disease and prescription of antiviral treatment to prevent the appearance of clinical disease). The drug used is intravenous or oral ganciclovir; oral valganciclovir; or, less frequently, valacyclovir. Prophylaxis should continue for 90 to 180 days. Treatment is always indicated in cytomegalovirus disease, and the gold-standard drug is intravenous ganciclovir. Treatment should be given for 2 to 3 weeks and should be continued for an additional 7 days after the first negative result for viremia.
bookPart Obesidade em Crianças e Adolescentes(2016) MANCINI, Marcio Correa; MELO, Maria Edna de; REINHARDT, Heidi Lui- Prevalence of latent Mycobacterium tuberculosis infection in hematopoietic stem cell transplantation comparing tuberculin skin test and interferon-gamma release assay(2023) CASTRO-LIMA, Victor A. C.; SANTOS, Ana Paula T.; MUSQUEIRA, Priscila T.; MALUF, Natalya Z.; RAMOS, Jessica F.; MARIANO, Livia; ROCHA, Vanderson; COSTA, Silvia F.The aim of this study was to evaluate the prevalence of latent Mycobacterium tuberculosis infection in hematopoietic stem cell transplantation candidates, using tuberculin skin test and QuantiFERON-TB Gold-Plus, in a high-burden tuberculosis country. Adult candidates for hematopoietic stem cell transplantation performed both tests before and those submitted to transplantation were followed up for 12 months. The prevalence of latent Mycobacterium tuberculosis infection was 17.1% and a moderate agreement between QuantiFERON-TB Gold-Plus and tuberculin skin test was observed in this population. Previous tuberculosis exposure was a risk factor for latent Mycobacterium tuberculosis infection. No cases of tuberculosis were diagnosed during follow-up period.
- Experience with SARS-CoV-2 in an orthopaedic hospital(2023) OLIVEIRA, Priscila R.; CARVALHO, Vladimir C.; ANJOS, Angelica M.; MELO, Vanessa F.; LEITE, Cesar; SILVA, Adriana C.; MALUF, Natalya Z.; SILVA, Jorge S.; LIMA, Ana Lucia L.Background: Concerns about nosocomial transmission of SARS-CoV-2 have been described since the COVID-19 pandemic was first reported and cases of hospital-acquired (HA) COVID-19 and COVID-19 outbreaks have been reported even in clinical areas not intended for the specific care of COVID-19 and declared as ""non-COVID"" areas. Methods: Retrospective analysis of measures to prevent of hospital acquisition of COVID19 in patients admitted to a tertiary referral specialist orthopaedic hospital in Brazil in which emergency care was maintained during the pandemic.Results: The proportion of HA-COVID-19 (0.07%) was lower than the value reported for general healthcare in Brazil (0.72%, P<0.001). The integration of several clinical teams to maintain a constant surveillance system, as well as the immediate isolation of patients with any compatible symptoms of COVID-19 and the restriction from work and the testing of symptomatic healthcare workers, were an important part of the strategies adopted.Conclusion: We suggest that the described strategies for preventing the nosocomial spread of SARS-CoV-2 contributed to the observed proportion of HA-COVID-19 to be significantly lower than the reported national value. Future studies that investigate these and other preventative measures are important so that hospitals are prepared for further periods of a high incidence of COVID-19, as well as for other epidemics associated with respiratory transmission.& COPY; 2022 The Authors.
- A Brazilian university hospital position regarding transplantation criteria for HIV-positive patients according to the current literature(2019) PIERROTTI, Lígia Camera; LITVINOV, Nadia; COSTA, Silvia Figueiredo; AZEVEDO, Luiz Sérgio Fonseca de; STRABELLI, Tânia Mara Varejão; CAMPOS, Silvia Vidal; ODONGO, Fatuma Catherine Atieno; REUSING-JUNIOR, Jose Otto; SONG, Alice Tung Wan; LOPES, Max Igor Banks Ferreira; BATISTA, Marjorie Vieira; LOPES, Marta Heloisa; MALUF, Natalya Zaidan; CAIAFFA-FILHO, Hélio Helh; DE OLIVEIRA, Maura Salarolli; SOUSA MARQUES, Heloisa Helena de; ABDALA, EdsonHuman immunodeficiency virus (HIV) infection was considered a contraindication for solid organ transplantation (SOT) in the past. However, HIV management has improved since highly active antiretroviral therapy (HAART) became available in 1996, and the long-term survival of patients living with HIV has led many transplant programs to reevaluate their policies regarding the exclusion of patients with HIV infection. Based on the available data in the medical literature and the cumulative experience of transplantation in HIV-positive patients at our hospital, the aim of the present article is to outline the criteria for transplantation in HIV-positive patients as recommended by the Immunocompromised Host Committee of the Hospital das Clínicas of the University of São Paulo.
- Management of post-transplant Epstein-Barr virus-related lymphoproliferative disease in solid organ and hematopoietic stem cell recipients(2014) MARQUES, Heloisa Helena de Sousa; SHIKANAI-YASUDA, Maria Aparecida; AZEVEDO, Luiz Sergio Fonseca de; CAIAFFA-FILHO, Helio Helh; PIERROTTI, Ligia Camera; AQUINO, Maria Zilda de; LOPES, Marta Heloisa; MALUF, Natalya Zaidan; CAMPOS, Silvia Vidal; COSTA, Silvia FigueiredoEpstein-Barr virus (EBV)-related post-transplant lymphoproliferative disease (PTLD) is one of the most serious complications associated with solid organ and hematopoietic stem cell transplantation. PTLD is most frequently seen with primary EBV infection post-transplant, a common scenario for pediatric solid organ recipients. Risk factors for infection or reactivation of EBV following solid organ transplant are stronger immunosuppressive therapy regimens, and being seronegative for receptor. For hematopoietic stem cell transplantation, the risk factors relate to the type of transplant, human leukocyte antigen disparity, the use of stronger immunosuppressants, T-cell depletion, and severe graft-versus-host disease. Mortality is high, and most frequent in patients who develop PTLD in the first six months post-transplant. The primary goal of this article is to provide an overview of the clinical manifestations, diagnosis, accepted therapies, and management of EBV infection in transplant recipients, and to suggest that the adoption of monitoring protocols could contribute to a reduction in related complications.
bookPart Obesidade no Adulto(2016) MANCINI, Marcio Correa; CERCATO, Cintia; HALPERN, Alfredo